1-Hydroxy-2-naphthoic acid
Based on 1 Customer Validation
1-Hydroxy-2-naphthoic acid is a ubiquitous bicyclic intermediate metabolite in the microbial degradation process of polycyclic aromatic hydrocarbons (PAHs). 1-Hydroxy-2-naphthoic acid can be converted into 1,2-naphthalenediol, which enters the naphthalene degradation pathway and participates in the tricarboxylic acid (TCA) cycle to achieve complete mineralization.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.57%
- CAS. Nr.: 86-48-6
- Formel: C11H8O3
- Molecular Weight:188.18
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Antibacterial Compound Library
HY-L049
-
Phenols Library
HY-L057
-
Human Metabolite Library
HY-L123
-
Cuproptosis Compound Library
HY-L133
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Bioactive Compound Library
HY-L001
-
RO5 Drug-like Natural Product Library
HY-L200
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Mass Spectrometry Natural Product Library
HY-L262
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Anti-Infection Compound Library
HY-L002
-
Natural Product Library
HY-L021
Biologische Aktivität
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MDCK | EC50 |
>1000000 nM
Compound: 4, HNAP
|
Antiviral activity against influenza A virus A/WSN/1933 (H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs
Antiviral activity against influenza A virus A/WSN/1933 (H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs
|
[PMID: 21778065] |
| MDCK | EC50 |
>100000 nM
Compound: HNAP
|
Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in MDCK cells assessed as inhibition of virus induced cytopathic effect
Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in MDCK cells assessed as inhibition of virus induced cytopathic effect
|
[PMID: 22963087] |
1-Hydroxy-2-naphthoic acid is a metabolic intermediate in the pyrene degradation pathway of Bacillus cereus strain C7[1].
1-Hydroxy-2-naphthoic acid is a metabolic intermediate in the phenanthrene degradation pathway of Burkholderia sp. FM-2[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 86-48-6
-
Appearance Solid
-
Molecular Weight 188.18
-
Formel C11H8O3
-
Color White to gray
-
SMILES
O=C(O)C1=CC=C2C=CC=CC2=C1O
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
DMSO : 50 mg/mL (265.70 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (6.64 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (6.64 mM); Suspended solution
This protocol yields a suspended solution of ≥ 1.25 mg/mL (saturation unknown). Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 5.3141 mL | 26.5703 mL | 53.1406 mL | 132.8515 mL |
| 5 mM | 1.0628 mL | 5.3141 mL | 10.6281 mL | 26.5703 mL | |
| 10 mM | 0.5314 mL | 2.6570 mL | 5.3141 mL | 13.2852 mL | |
| 15 mM | 0.3543 mL | 1.7714 mL | 3.5427 mL | 8.8568 mL | |
| 20 mM | 0.2657 mL | 1.3285 mL | 2.6570 mL | 6.6426 mL | |
| 25 mM | 0.2126 mL | 1.0628 mL | 2.1256 mL | 5.3141 mL | |
| 30 mM | 0.1771 mL | 0.8857 mL | 1.7714 mL | 4.4284 mL | |
| 40 mM | 0.1329 mL | 0.6643 mL | 1.3285 mL | 3.3213 mL | |
| 50 mM | 0.1063 mL | 0.5314 mL | 1.0628 mL | 2.6570 mL | |
| 60 mM | 0.0886 mL | 0.4428 mL | 0.8857 mL | 2.2142 mL | |
| 80 mM | 0.0664 mL | 0.3321 mL | 0.6643 mL | 1.6606 mL | |
| 100 mM | 0.0531 mL | 0.2657 mL | 0.5314 mL | 1.3285 mL |
1-Hydroxy-2-naphthoic acid Related Classifications
HY-W016103 Related Classifications
Powered by Bioz
- 1-Hydroxy-2-naphthoic acid
- 86-48-6
- Bacterial
- Drug Intermediate
- 1,2-naphthalenediol
- Burkholderia sp. FM-2
- Bacillus cereus C7
- phenanthrene
- tricarboxylic acid (TCA) cycle
- pyrene degradation pathway
- Burkholderia sp. FM-2::nahG
- naphthalene degradation pathway
- GC-MS analysis
- pyrene catabolism pathway
- Inhibitor
- inhibitor
- inhibit